Product Information
|
|
||||||
|
|
|||||
|
|
|
|
|||
Response |
|
|
|
|
||
|
|
|||||
ACR 20 | ||||||
Month 3 |
|
|
|
|
||
Month 6 |
|
|
|
|
||
ACR 50 | ||||||
Month 3 |
|
|
|
|
||
Month 6 |
|
|
|
|
||
a. 25 mg
ENBREL SC twice weekly.
b. 0.01, ENBREL vs. placebo. |
The time course for ACR 20 response rates for patients receiving placebo or 25 mg ENBREL in the two trials is summarized in the graph below:
Among patients receiving ENBREL, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. A dose response was seen in Study I; results with 10 mg were intermediate between placebo and 25 mg. ENBREL was significantly better than placebo in all components of the ACR criteria as well as other measures of RA disease activity not included in the ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ),7 which included disability, vitality, mental health, general health status, and arthritis-associated health status subdomains, was administered every 3 months during the trial. All subdomains of the HAQ were improved in patients treated with ENBREL compared to controls at 3 and 6 months. The table below shows the results of the components of the ACR response criteria for Study I. Findings were similar in Study II.
|
|||||
|
|
||||
Parameter (median) |
|
|
|
|
|
Number of tender joints b |
|
|
|
|
|
Number of swollen joints c |
|
|
|
|
|
Physician global assessment d |
|
|
|
|
|
Patient global assessment d |
|
|
|
|
|
Pain d |
|
|
|
|
|
Disability index e |
|
|
|
|
|
ESR (mm/hr) |
|
|
|
|
|
CRP (mg/dL) |
|
|
|
|
|
* Results
at 6 months showed similar improvement.
a. 25 mg ENBREL SC twice weekly. b. Scale 0-71. c. Scale 0-68. d. Visual analog scale; 0 = best, 10 = worst. |
|||||
An additional randomized, controlled, double-blind trial evaluated 180 patients with similar criteria to Study I.8 Doses of 0.25 mg/m2, 2 mg/m2, and 16 mg/m2 ENBREL were administered SC twice a week for 3 consecutive months. A dose-dependent increase in the proportion of subjects achieving an ACR 20 response was seen, with 75% of subjects responding in the highest dose group (16 mg/m2 ENBREL).
After discontinuation of ENBREL, symptoms of arthritis generally returned
within a month. Reintroduction of treatment with ENBREL after discontinuations
of up to 18 months resulted in the same magnitudes of response as patients
who received ENBREL without interruption of therapy based on results of
open-label studies. Continued durable responses have been seen for up to
18 months in open-label extension treatment trials when patients received
ENBREL without interruption.
Immunogenicity
Patients were tested at multiple timepoints for antibodies to ENBREL.
Antibodies to ENBREL, all nonneutralizing, were detected at least once
in sera of 16% of rheumatoid arthritis patients. No apparent correlation
of antibody development to clinical response or adverse events was observed.
The long-term immunogenicity of ENBREL is unknown.
INDICATIONS AND USAGE
ENBREL is indicated for reduction in signs and symptoms of moderately
to severely active rheumatoid arthritis in patients who have had an inadequate
response to one or more disease-modifying antirheumatic drugs (DMARDs).
ENBREL can be used in combination with methotrexate in patients who do
not respond adequately to methotrexate alone.
CONTRAINDICATIONS
ENBREL should not be administered to patients with sepsis or with known
hypersensitivity to ENBREL or any of its components.
WARNINGS
IN POST MARKETING REPORTS, SERIOUS INFECTIONS AND SEPSIS, INCLUDING
FATALATIES, HAVE BEEN REPORTED WITH THE USE OF ENBREL. MANY OF THESE
SERIOUS EVENTS HAVE OCCURRED IN PATIENTS WITH UNDERLYING DISEASES THAT
IN ADDITION TO THEIR RHEUMATOID ARTHRITIS COULD PREDISPOSE THEM TO INFECTIONS.
PATIENTS WHO DEVELOP A NEW INFECTION WHILE UNDERGOING TREATMENT WITH ENBREL
SHOULD BE MONITORED CLOSELY. ADMINISTRATION OF ENBREL SHOULD BE DISCONTINUED
IF A PATIENT DEVELOPS A SERIOUS INFECTION OR SEPSIS. TREATEMENT WITH
ENBREL SHOULD NOT BE INITIATED IN PATIENTS WITH ACTIVE INFECTIONS INCLUDING
CHRONIC OR LOCALIZED INFECTIONS. PHYSICIANS SHOULD EXERCISE CAUTION
WHEN CONSIDERING THE USE OF ENBREL IN PATIENTS WITH A HISTORY OF RECURRING
INFECTIONS OR WITH UNDERLYING CONDITIONS WHICH MAY PREDISPOSE PATIENTS
TO INFECTIONS SUCH AS ADVANCED OR POORLY CONTROLLED DIABETES. (see
PRECAUTIONS, ADVERSE
REACTIONS, INFECTIONS).
PRECAUTIONS
General
Allergic reactions associated with administration of ENBREL during clinical
trials have been reported rarely (<0.5%). If an anaphylactic reaction
or other serious allergic reaction occurs, administration of ENBREL should
be discontinued immediately and appropriate therapy initiated.
Information to Patients
If a patient is to self-administer ENBREL, they should be instructed
in injection techniques to ensure the safe self-administration of ENBREL
(see How to Use Enbrel, Instructions
for Preparing and Giving an Injection). The first injection should
be performed under the supervision of a qualified health care professional.
The ability of that patient to self-inject subcutaneously should be assessed.
A puncture-resistant container for disposal of needles and syringes should
be used. Patients should be instructed in the technique and told the importance
of proper syringe and needle disposal, and be cautioned against reuse of
these items.
Immunosuppression
The possibility exists for anti-TNF therapies, including ENBREL, to
affect host defenses against infections and malignancies since TNF mediates
inflammation and modulates cellular immune responses. In a study of 49
patients with RA treated with ENBREL, there was no evidence of depression
of delayed-type hypersensitivity, depression of immunoglobulin levels,
or change in enumeration of effector cell populations. The impact of treatment
with ENBREL on the development and course of malignancies and active and
/or chronic infections is not fully understood (see WARNINGS,
ADVERSE REACTIONS, Infections
and Malignancies). The safety and
efficacy of ENBREL in patients with immunosuppression or chronic infections
have not been evaluated.
Vaccinations
No data are available on the effects of vaccination in patients receiving
ENBREL. Live vaccines should not be given concurrently with ENBREL. No
data are available on the secondary transmission of infection by live vaccines
in patients receiving ENBREL (see PRECAUTIONS,
Immunosuppression).
Autoantibody Formation
Treatment with ENBREL may result in the formation of autoimmune antibodies
(see ADVERSE REACTIONS, Autoantibodies).
Drug Interactions
Specific drug interaction studies have not been conducted with ENBREL.
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies have not been conducted to evaluate the carcinogenic
potential of ENBREL or its effect on fertility. Mutagenesis studies were
conducted in vitro and in vivo, and no evidence of mutagenic activity was
observed.
Pregnancy (Category B)
Developmental toxicity studies have been performed in rats and rabbits
at doses ranging from 60- to 100-fold higher than the human dose and have
revealed no evidence of harm to the fetus due to ENBREL. There are, however,
no studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, this drug should be used during pregnancy
only if clearly needed.
Nursing Mothers
It is not known whether ENBREL is excreted in human milk or absorbed
systemically after ingestion. Because many drugs and immunoglobulins are
excreted in human milk, and because of the potential for serious adverse
reactions in nursing infants from ENBREL, a decision should be made whether
to discontinue nursing or to discontinue the drug.
Geriatric Use
A total of 123 RA patients ages 65 years or older have been studied in clinical trials. No overall differences in safety or effectiveness were observed between these patients and younger patients. Greater sensitivity of some older individuals cannot be ruled out.
In the open-label part of a two-part trial, 69 patients with polyarticular course JRA ages 4 to 17 years, who were refractory to or intolerant of methotrexate and had moderately to severely active JRA, were administered 0.4 mg/kg (maximum 25 mg dose) of ENBREL SC twice weekly for 3 months. Of 54 patients for whom 3-month treatment data were available, 76% demonstrated a clinical response measured by the JRA Definition of Improvement. The JRA Definition of Improvement is defined as 30% improvement in at least three of six and 30% worsening in no more than one of six JRA core set criteria, which include physician and patient global assessments, active joint count, limitation of motion, functional assessment, and ESR.9
Of 69 JRA patients for whom safety data were available, the safety profile was similar to that seen in adult RA patients treated with ENBREL. However, the percent of JRA patients reporting abdominal pain (17%) and vomiting (14.5%) was higher than in adult RA. While receiving ENBREL, two JRA patients developed varicella infection associated with signs and symptoms of aseptic meningitis; the infection resolved without sequelae. It is recommended that patients with a significant exposure to varicella virus temporarily discontinue ENBREL therapy and treatment with Varicella Zoster Immune Globulin be considered.
Responses to immunizations have not been studied in children receiving ENBREL. It is recommended that JRA patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating ENBREL therapy.
The safety of ENBREL has not been studied in children < 4 years of
age.
ADVERSE REACTIONS
ENBREL has been studied in 1039 patients with RA. In controlled studies,
349 patients received ENBREL and 152 patients received placebo. The proportion
of patients who discontinued treatment due to adverse events was the same
in both the ENBREL and placebo treatment groups (4%).
Injection Site Reactions
In controlled trials, 37% of patients treated with ENBREL developed
injection site reactions. All injection site reactions were described as
mild to moderate (erythema and/or itching, pain, or swelling) and generally
did not necessitate drug discontinuation. Injection site reactions generally
occurred in the first month and subsequently decreased in frequency. The
mean duration of injection site reactions was 3 to 5 days. Seven percent
of patients experienced redness at a previous injection site when subsequent
injections were given.
Infections
Upper respiratory infections ("colds") and sinusitis were the most frequently reported infections in patients receiving ENBREL or placebo. In placebo-controlled trials, the incidence of upper respiratory tract infections was 16% in the placebo treatment group and 29% in the group treated with ENBREL; and 0.68 events per patient year in the placebo group and 0.82 events per patient year in the group treated with ENBREL when the longer observation of patients on ENBREL was accounted for.
In placebo-controlled trials evaluating ENBREL, no increase in the incidence
of serious infections was observed (1.3% placebo, 0.9% ENBREL). In open-label
and placebo-controlled trials, 22 serious infections were observed in a
total of 745 subjects exposed to ENBREL, including: pyelonephritis, bronchitis,
septic arthritis, abdominal abscess, cellulitis, osteomyelitis, wound infection,
pneumonia, foot abscess, leg ulcer, diarrhea, sinusitis, and sepsis. Serious
infections, including sepsis and death, have also been reported during
post-marketing use of ENBREL. Some have occurred within a few weeks
after intitiating treatment with ENBREL. Many of the patients had
underlying conditions (e.g., diabetes, congestive heart failure, history
of active or chronic infections) in addition to their rheumatoid arthritis.
See WARNINGS. Data from a sepsis clinical
trial not specifically in patients with RA suggest that ENBREL treatment
may increase mortality in patients with established sepsis.10
Malignancies
Seven new malignancies of various types were observed in 745 RA patients
treated in clinical trials with ENBREL for up to 18 months. The observed
rates and incidences were similar to those expected for the population
studied.
Autoantibodies
Patients had serum samples tested for autoantibodies at multiple timepoints.
Of the patients evaluated for antinuclear antibodies (ANA), the percentage
of patients who developed new positive ANA (1:40)
was higher in patients treated with ENBREL (11%) than in placebo-treated
patients (5%). The percentage of patients who developed new positive anti-double
stranded DNA antibodies was also higher by radioimmunoassay (15% of patients
treated with ENBREL compared to 4% of placebo-treated patients) and by
crithidia lucilae assay (3% of patients treated with ENBREL compared to
none of placebo-treated patients). The proportion of patients treated with
ENBREL who developed anticardiolipin antibodies was similarly increased
compared to placebo-treated patients. No patients developed clinical signs
suggestive of a lupus-like syndrome or other new autoimmune diseases. The
impact of long-term treatment with ENBREL on the development of autoimmune
diseases is unknown.
Other Adverse Reactions
Events reported in at least 3% of all patients with higher incidence
in patients treated with ENBREL
compared to controls in placebo-controlled RA trials (including
the combination methotrexate trial) and events per patient year were as
follows:
|
|||||
|
|
||||
Event |
|
|
|
|
|
Injection site reaction |
|
|
|
|
|
Infection |
|
|
|
|
|
Non-upper respiratory infection** |
|
|
|
|
|
Upper respiratory infection** |
|
|
|
|
|
Headache |
|
|
|
|
|
Rhinitis |
|
|
|
|
|
Dizziness |
|
|
|
|
|
Pharyngitis |
|
|
|
|
|
Cough |
|
|
|
|
|
Asthenia |
|
|
|
|
|
Pain, abdomen |
|
|
|
|
|
Rash |
|
|
|
|
|
Respiratory disorder |
|
|
|
|
|
Dyspepsia |
|
|
|
|
|
Sinusitis |
|
|
|
|
|
* Includes
data from the 6-month study in which patients received concurrent methotrexate
therapy.
** Includes data from two of the three controlled trials. |
OVERDOSAGE
The maximum tolerated dose of ENBREL has not been established in humans.
Toxicology studies have been performed in monkeys at doses up to 30 times
the human dose with no evidence of dose-limiting toxicities. No dose-limiting
toxicities have been observed during clinical trials of ENBREL. Single
IV doses up to 60 mg/m2 have been administered to healthy volunteers
in an endotoxemia study without evidence of dose-limiting toxicities. The
highest dose level evaluated in RA patients has been a single IV loading
dose of 32 mg/m2 followed by SC doses of 16 mg/m2
(~25 mg) administered twice weekly. In one RA trial, one patient mistakenly
self-administered 62 mg ENBREL SC twice weekly for 3 weeks without experiencing
adverse effects.
DOSAGE AND ADMINISTRATION
The recommended dose of ENBREL for adult patients with rheumatoid arthritis
is 25 mg given twice weekly as a subcutaneous injection (see Clinical
Studies). Methotrexate, glucocorticoids, salicylates, nonsteroidal
anti-inflammatory drugs (NSAIDs), or analgesics may be continued during
treatment with ENBREL. Higher doses of ENBREL have not been studied. See
PRECAUTIONS, Pediatric Use for experience
in pediatric populations.
Preparation of ENBREL
ENBREL is intended for use under the guidance and supervision of a physician. Patients may self-inject only if their physician determines that it is appropriate and with medical follow-up, as necessary, after proper training in injection technique.
Note: The needle cover of the diluent syringe contains dry natural rubber (latex), which should not be handled by persons sensitive to this substance.
ENBREL should be reconstituted aseptically with 1 mL of the supplied Sterile Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol). During reconstitution of ENBREL, the diluent should be slowly injected into the vial. Some foaming will occur. To avoid excessive foaming, do not shake or vigorously agitate. The contents should be swirled gently during dissolution. Generally, dissolution of ENBREL takes less than 5 minutes. The reconstituted solution should be clear and colorless.
Visually inspect the solution for particulate matter and discoloration prior to administration. The solution should not be used if discolored or cloudy, or if particulate matter remains. Withdraw the solution into the syringe, removing as much liquid as possible from the vial. Some foam or bubbles may remain in the vial. The final volume in the syringe will be approximately 1 mL.
No other medications should be added to solutions containing ENBREL, and ENBREL should not be reconstituted with other diluents. Do not filter reconstituted solution during preparation or administration.
Sites for self-injection include thigh, abdomen, or upper arm. Injection
sites should be rotated. New injections should be given at least one inch
from an old site and never into areas where the skin is tender, bruised,
red, or hard. (See How to Use ENBREL,
Instructions for Preparing and Giving an Injection instruction sheet.)
Storage and Stability
Do not use a dose tray beyond the date stamped on the carton or vial label. The dose tray containing ENBREL (sterile powder) must be refrigerated at 2-8° C (36-46° F). Do not freeze.
Reconstituted solutions of ENBREL should be administered as soon as
possible after reconstitution. If not administered immediately after reconstitution,
ENBREL may be stored in the vial at 2-8ÁC (36-46ÁF) for up
to 6 hours.
HOW SUPPLIED
ENBREL is supplied in a carton containing four dose trays (NDC 58406-425-34). Each dose tray contains one 25 mg single-use vial of etanercept, one syringe (1 mL Sterile Bacteriostatic Water for Injection, USP, containing 0.9% benzyl alcohol), one plunger, and two alcohol swabs.
Rx only
REFERENCES
1. Feldman M, Brennan FM, Maini
RN. The role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;
14:397.
2. Saxne T, Palladino Jr MA,
Heinegard D, et al. Detection of tumor necrosis factor alpha but not tumor
necrosis factor beta in rheumatoid arthritis synovial fluid and serum.
Arthritis Rheum 1988;31:1041.
3. Smith CA, Farrah T, Goodwin
RG. The TNF receptor superfamily of cellular and viral proteins: activation,
costimulation, and death. Cell 1994;75:959.
4. Wooley PH, DutcherJ, Widmer
MB, et al. Influence of a recombinant human soluble tumor necrosis factor
receptor FC fusion protein on type II collagen-induced arthritis in mice.
J Immunol 1993;151:6602.
5. Data on file, Immunex Corporation.
6. Felson DT, Anderson JJ, Boers
M, et al. American College of Rheumatology preliminary definition of improvement
in rheumatoid arthritis. Arthritis Rheum 1995;6:727.
7. Ramey DR, Fries JF, Singh
G. The Health Assessment Questionnaire 1995 Ü Status and Review. In:
Spilker B, ed. "Quality of Life and Pharmacoeconomics in Clinical Trials."
2nd ed. Philadelphia, PA. Lippincott-Raven; 1996.
8. Moreland LW, Baumgartner SW,
Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant
human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J
Med 1997;337(3):141.
9. Giannini EH, Ruperto N, Ravelli
A, et al. Preliminary definition of improvement in juvenile arthritis.
Arthr Rheum 1997;40(7):1202.
10. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334(26):1697.
Issue Date 05/1999
Manufactured by:
Immunex Corporation
Seattle, Washington 98101
U.S. License Number 1132
Marketed by Immunex Corporation and Wyeth-Ayerst Laboratories
© 1999 Immunex Corporation
Immunex U.S. Patent Numbers:
5,605,690;5,712,155;5,395,790